fentanyl has been researched along with Disease Exacerbation in 12 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 9.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 9.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 microg in the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 9.14 | Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen ( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009) |
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 9.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 5.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 5.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 microg in the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 5.14 | Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen ( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009) |
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 5.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "In this cohort study of patients admitted to the ED with confirmed opioid overdose testing positive for NPOs, in-hospital naloxone dosing was high compared with patients who tested positive for fentanyl alone." | 1.91 | Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. ( Abston, S; Aldy, K; Amaducci, A; Brent, J; Campleman, SL; Culbreth, RE; Krotulski, A; Li, S; Logan, B; Manini, AF; Meyn, A; Wax, P, 2023) |
| "Fentanyl efficacy was not statistically related to age, gender, cancer type, previous opioid treatment, steroid and midazolam doses and PPS." | 1.51 | Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. ( Benítez-Rosario, MA; González-Dávila, E; Rosa-González, I; Sanz, E, 2019) |
| "Postoperative cerebral infarction was defined as a diffusion-weighted imaging high-intensity lesion with or without symptoms." | 1.48 | Postoperative Cerebral Infarction Risk Factors and Postoperative Management of Pediatric Patients with Moyamoya Disease. ( Araki, Y; Kondo, G; Kurimoto, M; Muraoka, S; Okamoto, S; Ota, S; Shiba, Y; Uda, K; Wakabayashi, T, 2018) |
| "The first patient had a cardiac arrest whereas the second developed respiratory failure and altered neurological status." | 1.32 | Two cases of hemorrhage secondary to amniotic fluid embolus managed with uterine artery embolization. ( Davies, S; Goldszmidt, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Amaducci, A | 1 |
| Aldy, K | 1 |
| Campleman, SL | 1 |
| Li, S | 1 |
| Meyn, A | 1 |
| Abston, S | 1 |
| Culbreth, RE | 1 |
| Krotulski, A | 1 |
| Logan, B | 1 |
| Wax, P | 1 |
| Brent, J | 1 |
| Manini, AF | 1 |
| Switzer, AR | 1 |
| Beland, B | 1 |
| Sarna, JR | 1 |
| Walzak, A | 1 |
| Pfeffer, G | 1 |
| Muraoka, S | 1 |
| Araki, Y | 1 |
| Kondo, G | 1 |
| Kurimoto, M | 1 |
| Shiba, Y | 1 |
| Uda, K | 1 |
| Ota, S | 1 |
| Okamoto, S | 1 |
| Wakabayashi, T | 1 |
| Benítez-Rosario, MA | 1 |
| Rosa-González, I | 1 |
| González-Dávila, E | 1 |
| Sanz, E | 1 |
| Elsner, F | 1 |
| Pastrana, T | 1 |
| Fujii, T | 1 |
| Takana, K | 1 |
| Orita, S | 1 |
| Inoue, G | 1 |
| Ochiai, N | 1 |
| Kuniyoshi, K | 1 |
| Aoki, Y | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Kamoda, H | 1 |
| Suzuki, M | 1 |
| Sakuma, Y | 1 |
| Kubota, G | 1 |
| Oikawa, Y | 1 |
| Inage, K | 1 |
| Sainoh, T | 1 |
| Sato, J | 1 |
| Yamauchi, K | 1 |
| Toyone, T | 1 |
| Nakamura, J | 1 |
| Kishida, S | 1 |
| Takahashi, K | 1 |
| Ohtori, S | 1 |
| Simon, ST | 1 |
| Kloke, M | 1 |
| Alt-Epping, B | 1 |
| Gärtner, J | 1 |
| Hellmich, M | 1 |
| Hein, R | 1 |
| Piel, M | 1 |
| Cornely, OA | 1 |
| Nauck, F | 1 |
| Voltz, R | 1 |
| Weinstein, SM | 1 |
| Messina, J | 1 |
| Xie, F | 1 |
| Kress, HG | 1 |
| Orońska, A | 1 |
| Kaczmarek, Z | 1 |
| Kaasa, S | 1 |
| Colberg, T | 1 |
| Nolte, T | 1 |
| Goldszmidt, E | 1 |
| Davies, S | 1 |
| Allan, L | 1 |
| Richarz, U | 1 |
| Simpson, K | 1 |
| Slappendel, R | 1 |
| Hamaguchi, S | 1 |
| Kitajima, T | 1 |
| Yasuda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures[NCT01756651] | Phase 1 | 20 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for fentanyl and Disease Exacerbation
7 other studies available for fentanyl and Disease Exacerbation
| Article | Year |
|---|---|
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients.
Topics: Adult; Analgesics, Opioid; Cohort Studies; Disease Progression; Drug Overdose; Emergency Service, Ho | 2023 |
Fentanyl Overdose Causing Hippocampal Ischaemia Followed by Delayed Leukoencephalopathy.
Topics: Analgesics, Opioid; Brain Ischemia; Disease Progression; Fentanyl; Hippocampus; Humans; Hypoventilat | 2020 |
Postoperative Cerebral Infarction Risk Factors and Postoperative Management of Pediatric Patients with Moyamoya Disease.
Topics: Adolescent; Analgesics; Barbiturates; Cerebral Infarction; Cerebral Revascularization; Child; Child, | 2018 |
Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2019 |
[Cancer patient with breakthrough pain].
Topics: Aged; Analgesics, Opioid; Breakthrough Pain; Breast Neoplasms; Disease Progression; Dose-Response Re | 2013 |
Two cases of hemorrhage secondary to amniotic fluid embolus managed with uterine artery embolization.
Topics: Adult; Amides; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthetics, | 2003 |
[Anesthetic management of a patient with postthymectomy myasthenia gravis].
Topics: Anesthesia, Epidural; Anesthesia, General; Anesthetics, Intravenous; Disease Progression; Fentanyl; | 1999 |